Jefferies analyst Chris Howerton downgrades Applied Molecular (NASDAQ:AMTI) from Buy to Hold.
Goldman Sachs Downgrades Harmony Biosciences to Neutral, Announces $55 Price Target
Goldman Sachs analyst Corinne Jenkins downgrades Harmony Biosciences (NASDAQ:HRMY) from Buy to Neutral and announces $55 price target.